It has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way […] Read more
Genomic alterations drive more than 60% of adenocarcinoma cases of NSCLC.1 Approximately 25% of these cases will have an oncogenic driver (EGFR, ALK, ROS1, BRAF, or NTRK) that can be […] Read more
By Jill Feldman, EGFR Resisters Co-Founder Posted: December 11, 2019 Jill Feldman I was so glad to see the article by Dr. Amy Moore on PDX models in the October […] Read more